Evaluating a Specific Dual ROCK Inhibitor against Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease. Rho-associated protein kinases (ROCK) 1/2 are promising therapeutic targets for the treatment of IPF. However, a single inhibition of each of them is insufficient to prevent bleomycin-induced lung fibrosis. The current work reported that bleomycin-induced lung fibrosis can be reduced by dual inhibition of ROCK1/2 with compound 1. We evaluated the dual-selective ROCK1/2 inhibition activity of compound 1, its toxicity, and its preliminary efficacy on bleomycin-induced lung fibrosis. In vitro, compound 1 served as the ROCK1/2 inhibitor with half-maximal inhibitory concentration (IC 50 ) values of 165 ±10.4 nM for ROCK1 and 16.1 ± 2.82 nM for ROCK2. In NIH/3T3 cells, compound 1 inhibited the mRNA expression of COL 1A1 and α-SMA. At therapeutic levels, compound 1 exhibited neither hepatic nor cardiac toxicity, also no CYP450 enzyme inhibition. In vivo, compound 1 had good pharmacokinetic properties, and its oral administration reduced bleomycin-induced pulmonary fibrosis in rats. All the outcomes prove the drug-like characteristics of compound 1 for the treatment of IPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vitro studies demonstrated inhibited TGF-β1 expression and reduced levels TGF-β1 mRNA levels after treatment with siRNA TRK-250, suggesting a potential therapeutic effect in IPF.[152].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [152]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Wells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 569
Ahluwalia, N., Shea, B. S., & Tager, A. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0509pp · Cited by 235
Knipe, R. S., Tager, A. M., & Liao, J. K. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009381 · Cited by 233
Sun, K.-H., Chang, Y., Reed, N. I., & Sheppard, D. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00350.2015 · Cited by 198
Knipe, R. S., Probst, C. K., Lagares, D., Franklin, A., Spinney, J. J., Brazee, P. L., Grasberger, P., Zhang, L., Black, K. E., Sakai, N., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0075oc · Cited by 117
Cited by
EP300 as a Molecular Integrator of Fibrotic Transcriptional Programs
Rubio, K., Molina-Herrera, A., Pérez-González, A., Hernández‐Galdámez, H. V., Piña‐Vázquez, C., Araujo-Ramos, T., & Singh, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512302 · Cited by 51
Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)
Aribindi, K., Liu, G. Y., & Albertson, T. E. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2396121 · Cited by 17
Saadh, M. J., Sharma, P., Naser, I. H., Kumar, A., Kumar, M. R., Rasulova, I., Mohammed, F., Allela, O. Q. B., Mohammed, W. K., Ahmed, N., et al. (2024) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.23790 · Cited by 11
The importance of mechanical forces in chronic respiratory diseases
Burgess, J. K., Nawroth, J. C., Ibáñez‐Fonseca, A., & Gavara, N. (2026) · European Respiratory Review · doi:10.1183/16000617.0155-2025 · Cited by 10
Epigenetic targets and their inhibitors in the treatment of idiopathic pulmonary fibrosis
Miao, X., Liu, P., Liu, Y., Zhang, W., Li, C., & Wang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117463 · Cited by 8
Metadata
- Authors
- Liu, L., Song, W., Zeng, J., & Peng, Z.
- Affiliations
- Wuhan Createrna Science and Technology Co.Ltd, Wuhan East Lake High-Tech Development Zone, Biolake C2-2, Wuhan 430073, China
- Hubei University (CN)
- Corresponding author
- Liu, Li
- Peng, Zhihong
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-08-11
- Volume
- 5
- Issue
- 9
- Pages
- 819-828
- ISSN
- 2575-9108 (ISSN-L)
- PMC
- PMC9469187
- OpenAlex
- W4292768939
- Cited by
- 8
- References
- 19
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Pharmacology & Translational Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wuhan Createrna Science and Technology Co.Ltd
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- idiopathic pulmonary fibrosis, bleomycin-induced lung fibrosis, Rho kinase, compound 1, drug-likeness, pharmacokinetics, hepatotoxicity, cardiotoxicity, COL1A1, alpha-smooth muscle actin, antifibrotic therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating a Specific Dual ROCK Inhibitor against Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats. https://app.cochat.ai/papers/10.1021/acsptsci.2c00149
- The paper
- Liu, L., Song, W., Zeng, J., & Peng, Z. (2022). Evaluating a Specific Dual ROCK Inhibitor against Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.2c00149
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.